We are live on ! Find out more
LOAMS

Lombard Odier Asset Management (Switzerland) Portfolio holdings

AUM $2.63B
1-Year Est. Return 31.52%
This Fund
S&P 500
This Quarter Est. Return
-6.61%
1 Year Est. Return
+31.52%
3 Year Est. Return
+98.77%
5 Year Est. Return
+107.98%
10 Year Est. Return
+494.97%
AUM
$1.27B
AUM Growth
-$291M
Cap. Flow
-$139M
Cap. Flow %
-10.93%
Top 10 Hldgs %
24.84%
Holding
415
New
40
Increased
54
Reduced
57
Closed
258

Top Buys

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$34.3M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$24.4M
3
INCY icon
Incyte
INCY
+$24.2M
4
ELS icon
Equity Lifestyle Properties
ELS
+$23.2M
5
BMY icon
Bristol-Myers Squibb
BMY
+$22.7M

Top Sells

Rank Stock Value
1
PHM icon
Pultegroup
PHM
+$28.6M
2
BIIB icon
Biogen
BIIB
+$24.6M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$24.1M
4
ABT icon
Abbott
ABT
+$16.3M
5
POOL icon
Pool Corp
POOL
+$14.2M

Sector Composition

Rank Sector Weight
1 Healthcare 56.62%
2 Financials 13.8%
3 Consumer Discretionary 12.01%
4 Technology 6.24%
5 Energy 3.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KEYS icon
26
Keysight
KEYS
$60.6B
$20.7M 1.62%
130,737
+7,138
+6% +$1.19M
BNTX icon
27
BioNTech
BNTX
$23.3B
$20.4M 1.6%
+119,311
New +$20M
BAX icon
28
Baxter International
BAX
$13.9B
$20.3M 1.59%
261,255
+257,223
+6,380% +$21.5M
IRTC icon
29
iRhythm Holdings
IRTC
$4.13B
$20.2M 1.59%
128,518
-32,825
-20% -$4.22M
AAPL icon
30
Apple
AAPL
$4.41T
$19.2M 1.51%
109,961
-11,229
-9% -$1.89M
MDRX
31
DELISTED
Veradigm Inc. Common Stock
MDRX
$19.1M 1.5%
848,645
+57,484
+7% +$1.16M
ABT icon
32
Abbott
ABT
$192B
$18.6M 1.46%
157,492
-131,162
-45% -$16.3M
NBIX icon
33
Neurocrine Biosciences
NBIX
$15.9B
$17.9M 1.4%
190,568
-72,097
-27% -$6.11M
RCM
34
DELISTED
R1 RCM Inc. Common Stock
RCM
$17.6M 1.38%
659,521
+81,723
+14% +$2M
DXCM icon
35
DexCom
DXCM
$34.3B
$16M 1.25%
125,056
+123,248
+6,817% +$13.5M
MSFT icon
36
Microsoft
MSFT
$3.66T
$15.5M 1.21%
50,133
-1,422
-3% -$428K
ALNY icon
37
Alnylam Pharmaceuticals
ALNY
$30B
$13.6M 1.06%
+83,038
New +$12.7M
MFC icon
38
Manulife Financial
MFC
$72.6B
$12.9M 1.01%
+604,270
New +$12.4M
CHE icon
39
Chemed
CHE
$7.07B
$12.7M 0.99%
25,000
-25,000
-50% -$12M
VRTS icon
40
Virtus Investment Partners
VRTS
$1.12B
$12M 0.94%
50,000
+10,000
+25% +$2.52M
CRSP icon
41
CRISPR Therapeutics
CRSP
$5.22B
$12M 0.94%
190,685
+12,916
+7% +$811K
APLS
42
DELISTED
Apellis Pharmaceuticals
APLS
$11.2M 0.88%
221,251
-202,425
-48% -$8.94M
AMED
43
DELISTED
Amedisys
AMED
$11.2M 0.88%
+65,000
New +$9.71M
IMGN
44
DELISTED
Immunogen Inc
IMGN
$10.8M 0.85%
2,275,409
-1,168,115
-34% -$6.47M
TWST icon
45
Twist Bioscience
TWST
$7.85B
$10.6M 0.83%
214,701
+14,543
+7% +$806K
SWAV
46
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$10.1M 0.79%
+48,739
New +$8.04M
SGFY
47
DELISTED
Signify Health, Inc.
SGFY
$9.57M 0.75%
527,393
+198,048
+60% +$2.84M
TDOC icon
48
Teladoc Health
TDOC
$1.22B
$9.33M 0.73%
129,318
-75,221
-37% -$5.42M
EXAS
49
DELISTED
Exact Sciences
EXAS
$8.54M 0.67%
122,209
-55,939
-31% -$4.09M
UTHR icon
50
United Therapeutics
UTHR
$21.9B
$8.45M 0.66%
+47,079
New +$8.97M
1
2
3 4 5

Similar funds

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
CCM
Cerberus Capital Management New York $2.65B AUM 20.18% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return
PCIG
Partners Capital Investment Group Boston, Massachusetts $2.65B AUM 16.42% 1-Year Est. Return
MAMU
Marathon Asset Management (UK) London, United Kingdom $2.61B AUM 27.14% 1-Year Est. Return

Lombard Odier Asset Management (Switzerland)'s Q1 2022 Portfolio in Review

As of Q1 2022, Lombard Odier Asset Management (Switzerland) held 415 positions worth $1.27B, down 19% from $1.57B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Lombard Odier Asset Management (Switzerland) withdrew a net $139M in Q1 2022, closing 258 positions and reducing 57 holdings. Its most notable exit was Pultegroup, an estimated $28.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, up from 53% a quarter earlier, followed by Financials and Consumer Discretionary.

Against the trend, Lombard Odier Asset Management (Switzerland) opened a new position in BioMarin Pharmaceuticals worth $22.5M.

  • Lombard Odier Asset Management (Switzerland)'s largest Q1 2022 buy was BioMarin Pharmaceuticals: 291,870 shares worth $22.5M.
  • Lombard Odier Asset Management (Switzerland) added most to CVS Health in Q1 2022, an estimated $34.3M increase.
  • Lombard Odier Asset Management (Switzerland)'s biggest Q1 2022 reduction was Abbott, cutting an estimated $16.3M.
  • Lombard Odier Asset Management (Switzerland) fully exited Pultegroup in Q1 2022, selling an estimated $28.6M.
  • Lombard Odier Asset Management (Switzerland)'s ten largest holdings make up 25% of its $1.27B portfolio in Q1 2022.
  • Lombard Odier Asset Management (Switzerland) opened 40 new positions and closed 258 in Q1 2022.
  • Lombard Odier Asset Management (Switzerland)'s portfolio value fell 19% quarter-over-quarter to $1.27B.

Based on Lombard Odier Asset Management (Switzerland)'s 13F filing for Q1 2022, filed 16 May 2022.